Digoxin
- Generic Name
- Digoxin
- Brand Names
- Digox, Lanoxin
- Drug Type
- Small Molecule
- Chemical Formula
- C41H64O14
- CAS Number
- 20830-75-5
- Unique Ingredient Identifier
- 73K4184T59
- Background
Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
...
- Indication
Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.
...
- Associated Conditions
- Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure
- Associated Therapies
- -
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 72
- Registration Number
- NCT06416800
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Jemincare
- Target Recruit Count
- 72
- Registration Number
- NCT06348290
A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
- Conditions
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT06335134
- Locations
- 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Eccogene
- Target Recruit Count
- 48
- Registration Number
- NCT06293742
- Locations
- 🇺🇸
Eccogene Investigational Site, Anaheim, California, United States
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06194214
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
- Conditions
- Interventions
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT06186622
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc., Dallas, Texas, United States
A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 35
- Registration Number
- NCT06111521
- Locations
- 🇺🇸
ICON Early Clinical & Bioanalytical Solutions, Salt Lake City, Utah, United States
A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-01-11
- Target Recruit Count
- 28
- Registration Number
- NCT06092931
- Locations
- 🇺🇸
ICON Phase 1 Clinic, Salt Lake City, Utah, United States
Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid
- Conditions
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 49
- Registration Number
- NCT05954624
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou University of Chinese medicine, Guangzhou, China
A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT05852769
- Locations
- 🇺🇸
ICON plc, Millcreek, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.